

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
DTCP-HIB-MCV4 COMBINED VACCINE OBTAINS CLINICAL TRIAL
APPROVAL IN CHINA

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that it has obtained clinical trial approval granted by the National Medical Products Administration of the People's Republic of China to initiate relevant clinical trial for the Company's absorbed diphtheria, tetanus and acellular pertussis (components) (the “**DTcP**”) Haemophilus Influenzae Type b (Conjugate) (the “**Hib**”) – Group ACYW135 Meningococcal (Conjugate) (the “**MCV4**”) combined vaccine (the “**DTcP-Hib-MCV4 Combined Vaccine**”), a vaccine candidate developed by the Company.

As of the date of this announcement, as a component of the DTcP-Hib-MCV4 Combined Vaccine, the Company's Menhycia[®], as the first MCV4 vaccine product in China, has obtained the new drug approval and achieved commercialization, the DTcP Infant is under the Phase III clinical trial, and the Hib Vaccine is under the Phase I clinical trial. Based on the relevant data accumulated during the development of these vaccines, the Company intends to develop the DTcP-Hib-MCV4 Combined Vaccine in order to meet the market demand for combined vaccines, establishing a differentiated competitive advantage for the Company.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, February 24, 2025

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Shuifa GUI, Mr. Jianzhong LIU and Mr. Yiu Leung Andy CHEUNG as independent non-executive Directors.